Dr. Wilding is one of the first ophthalmologists in the area to offer the new FDA approved intraocular lens (IOL), AcrySof® ReSTOR®. This revolutionary lens is used for bi-focal cataract surgery. 

In clinical trials, 80 percent of patients reported "never" wearing reading glasses or bifocals following bilateral cataract surgery. The vast majority of patients who undergo cataract surgery today receive traditional IOLs, which typically require patients to use reading glasses or bifocals for near vision following surgery.

The AcrySof® ReSTOR® lens is a foldable IOL that represents breakthrough technology because of its unique, patented optic design, which allows patients to experience the highest level of freedom from glasses ever achieved in IOL clinical trials. The AcrySof® ReSTOR® IOL uses a combination of three complementary technologies: apodization, diffraction and refraction, to allow patients to experience a full range of high-quality vision without the need for reading glasses or bifocals. This range of vision without glasses is achieved through the optical properties of the IOL. The benefit for patients is a high level of spectacle freedom. Alcon, Inc. has patented the application of apodization technology to an IOL, making the AcrySof® ReSTOR® lens the first and only apodized diffractive IOL.

AcrySof® ReSTOR® IOL does not rely on the ciliary muscle, which weakens with age, to enable the eye to quickly change focus to see objects at near, intermediate and far distances. This allows 80 percent of cataract patients with and without presbyopia (age-related vision loss) the ability to see clearly without the aid of glasses or bifocals.

Clinical trials were conducted in the United States and Europe to establish the safety and effectiveness of the AcrySof® ReSTOR® IOL. A total of 566 people received the AcrySof® ReSTOR® lens in the clinical trials.  Since its introduction outside the U.S. in 2003, more than 11,000 AcrySof® ReSTOR® IOLs have been implanted in patients by more then 900 surgeons in Europe and in other countries.

A cataract is a "clouding" of the eye's natural lens, which results in blurred or defocused vision. According to a recent article published in the Archives of Ophthalmology, more than 20 million adults in the U.S. have developed cataracts making it the number one cause of poor vision in the United States. While not all cataracts require surgery, nearly three million cataract procedures are performed annually in the U.S. Cataracts cannot be prevented and are the leading cause of treatable blindness worldwide. According to the National Eye Institute, the number of Americans with cataracts is expected to increase to over 30 million people by the year 2020.

For the last two years, RestorVision has amazed scientists and eye surgeons with its revolutionary microscopic Reading Implant^TM; that when placed in the sclera, or white portion, of only one eye enabled presbyopic patients to read small print with either or both eyes. All patients that have undergone the procedure have improved their vision and were able to immediately read following their surgery without the use of reading glasses or bifocals.  Many patients are now two years post operative and still enjoying their eyesight without glasses.

This new option for cataract surgery is available now from Dr. John Wilding at Ohio Vision.  He serves the community in Sidney, St. Marys, Celina and Bellefontaine.  Call Ohio Vision at       937-492-8040 for further information.